A Decision Theory Analysis of Radiotherapeutic and Chemotherapeutic Toxicity in the Management of Ovarian Cancer

  • R. A. Potish
  • L. B. Twiggs


Many decisions in the management of cancer contain a component of uncertainty. A treatment which benefits one patient may harm another patient. An ‘average’ response to therapy is only occasionally observed: some patients respond surprisingly well, while others fare unexpectedly poorly. A particularly frustrating manifestation of these elements of probability is the apparent randomness of therapeutic successes and failures in patients who appear to be closely matched for all known prognostic factors.


Ovarian Cancer Small Bowel Obstruction Decision Theory Gynaecological Oncology Expected Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dembo AJ (1982) The role of radiotherapy in ovarian cancer. Bull Cancer (Paris) 69:275–283Google Scholar
  2. 2.
    Delclos L, Dembo AJ (1980) Female pelvis: ovaries. In: Fletcher GH (ed) Textbook of Radiotherapy, Lea & Febiger, Philadelphia, 3rd edn. pp 834–851Google Scholar
  3. 3.
    Potish RA, Twiggs LB, Adcock LL, Prem KA (to be published) Logistic models for prediction of enteric morbidity in the treatement of ovarian and cervical cancers. J Obstet GynecolGoogle Scholar
  4. 4.
    Cox DR (1969) The analysis of binary data. Methuen, London, pp 87–91Google Scholar
  5. 5.
    Greene MH, Boice JD Jr, Greer BE, Blessing JA, Dembo AJ (1982) Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: A study of five randomized clinical trials. New Engl J Med 307:1416–1421PubMedCrossRefGoogle Scholar
  6. 6.
    Smith JP, Rutledge FN, Delclos L (1975) Postoperative treatment of early cancer of the ovary: A random trial between postoperative irradiation and chemotherapy, Natl Cancer Inst Monogr 42:149–153PubMedGoogle Scholar
  7. 7.
    Einhorn N (1978) Acute leukemia after chemotherapy (melphalan). Cancer 41:444–447PubMedCrossRefGoogle Scholar
  8. 8.
    Chernoff H, Moses LE (1959) Elementary decision theory. Wiley, New York, pp 1–11Google Scholar
  9. 9.
    Smith JP, Rutledge F (1970) Chemotherapy in the treatment of cancer of the ovary, Am J Obstet Gynecol 107:691–703PubMedGoogle Scholar
  10. 10.
    Potish R, Adcock L, Brooker D, Jones TK Jr, Levitt SH, Okagaki T, Prem K (1980) Sequential surgery, radiation therapy, and Alkeran in the management of epithelial carcinoma of the ovary. Cancer 45:2754–2758PubMedCrossRefGoogle Scholar
  11. 11.
    Brady LW, Blessing JA, Slayton RE, Homesley HD, Lewis GC (1979) Radiotherapy (RT), chemotherapy (CT), and combined therapy in Stage III epithelial ovarian cancer, Cancer Clin Trials 2:111–120Google Scholar
  12. 12.
    Omura GA, Morrow CP, Blessing JA, Miller A, Buchsbaum HJ, Homesley HD, Leone L (1983) A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian cancer. Cancer 51:783–789PubMedCrossRefGoogle Scholar
  13. 13.
    Schmähl D, Habs M, Lorenz M, Wagner I (1982) Occurrence of second tumors in man after anticancer drug treatment. Cancer Treat Rev 9:167–194PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • R. A. Potish
  • L. B. Twiggs

There are no affiliations available

Personalised recommendations